172 related articles for article (PubMed ID: 8097937)
1. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
Klumpp TR; Mangan KF; Glenn LD; Macdonald JS
Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937
[TBL] [Abstract][Full Text] [Related]
2. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
Myers SE; Mick R; Williams SF
Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
[TBL] [Abstract][Full Text] [Related]
4. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
5. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue.
Spitzer TR; Cirenza E; McAfee S; Foelber R; Zarzin J; Cahill R; Mazumder A
Bone Marrow Transplant; 1995 Apr; 15(4):537-42. PubMed ID: 7655378
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[TBL] [Abstract][Full Text] [Related]
10. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
14. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
15. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
16. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
19. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
[TBL] [Abstract][Full Text] [Related]
20. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
